Hodgkin disease/lymphoma (HD/HL) is an uncommon malignancy; in 2008, an estimated 8220 new diagnoses and 1350 deaths will occur in the United States. The past few decades have seen significant progress in the management of HL; it is now curable in at least 80% of patients. In fact, cure rates for HL have increased so extensively that the overriding treatment considerations often relate to long-term toxicity, especially for patients with early- or intermediate-stage disease. The World Health Organization classification divides HL into 2 main types: classical and lymphocyte-predominant HL (CHL and LPHL). These guidelines discuss clinical management, focusing exclusively on patients from postadolescence through the seventh decade of life who do not have serious intercurrent disease. For the most recent version of the guidelines, please visit NCCN.org